Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults aged 18-59 years;~* Proven legal identity;~* Participants should be capable of understanding the informed consent form, and such form should be signed prior to enrolment ;~Exclusion Criteria:~* Travel history / residence history of Wuhan city and surrounding areas, or other communities with case reports within 14 days;~* History of contact with a SARS-CoV-2 infection (positive in nucleic acid test) within 14 days;~* Have contacted patients with fever or respiratory symptoms from Wuhan and surrounding areas, or from communities with case reports within 14 days;~* Have contacted patients with fever or respiratory symptoms from Wuhan and surrounding areas, or from communities with case reports within 14 days;~* Self-reported history of SARS;~* Self-reported history of new coronavirus infection;~* Positive in serum antibodies (IgG or IgM) screening of COVID-19;~* Positive in nasopharyngeal swabs or anal swabs through RT-PCR;~* Women who are breastfeeding, pregnant or planning to become pregnant during the study period;~* BMI≥35 kg/m2;~* History of asthma, history of allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea, and angioedema;~* Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;~* Autoimmune disease or immunodeficiency / immunosuppression;~* Suffering from severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver and kidney diseases, malignant tumors, etc.;~* Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;~* Thyroid disease or history of thyroidectomy, spleenlessness, functional spleenlessness, spleenlessness or splenectomy resulting from any condition;~* Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;~* Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute non-complicated dermatitis superficial corticosteroid therapy) in the past 6 months;~* Abnormal laboratory test results in the physical examination such as clinically significant abnormal hematology and biochemistry beyond the reference value range (only applicable to Phase I clinical trials);~* History of alcohol or drug abuse;~* Receipt of blood products within in the past 3 months;~* Receipt of other investigational drugs in the past 30 days;~* Receipt of attenuated live vaccines in the past 14 days;~* Receipt of inactivated or subunit vaccines in the past 7 days;~* Attacks of acute diseases or chronic diseases in the past 7 days;~* Axillary temperature \>37.0°C;~* According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- Emergency schedule & Two doses of medium dosage vaccine (Type: EXPERIMENTAL): 24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with medium dosage vaccine 6 months after the emergency schedule
- Emergency schedule & Two doses of high dosage vaccine (Type: EXPERIMENTAL): 24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with high dosage vaccine 6 months after the emergency schedule
- Emergency schedule &Two doses of placebo (Type: PLACEBO_COMPARATOR): 24 participants in phase Ⅰand 30 participants in phase Ⅱ will receive two doses of placebo at the emergency vaccination schedule,and 30 participants in phase Ⅱ will receive one dose of booster immunization with placebo 6 months after the emergency schedule
- Routine schedule & Two doses of medium dosage vaccine (Type: EXPERIMENTAL): 24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with medium dosage vaccine 6 months after the routine schedule
- Routine schedule &Two doses of high dosage vaccine (Type: EXPERIMENTAL): 24 participants in phase Ⅰand 60 participants in phase Ⅱ will receive two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule,and 60 participants in phase Ⅱ will receive one dose of booster immunization with high dosage vaccine 6 months after the routine schedule
- Routine schedule & Two doses of placebo (Type: PLACEBO_COMPARATOR): 24 participants in phase Ⅰand 30 participants in phase Ⅱ will receive two doses of placebo at the routine vaccination schedule,and 30 participants in phase Ⅱ will receive one dose of booster immunization with placebo 6 months after the routine schedule
- Emergency schedule & Three doses of medium dosage vaccine (Type: EXPERIMENTAL): 60 participants in phase Ⅱ will receive three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
- Emergency schedule & Three doses of high dosage vaccine (Type: EXPERIMENTAL): 60 participants in phase Ⅱ will receive three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
- Emergency schedule &Three doses of placebo (Type: PLACEBO_COMPARATOR): 30 participants in phase Ⅱ will receive three doses of placebo at the emergency vaccination schedule
- Routine schedule & Three doses of medium dosage vaccine (Type: EXPERIMENTAL): 60 participants in phase Ⅱ will receive three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
- Routine schedule &Three doses of high dosage vaccine (Type: EXPERIMENTAL): 60 participants in phase Ⅱ will receive three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
- Routine schedule &Three doses of placebo (Type: PLACEBO_COMPARATOR): 30 participants in phase Ⅱ will receive three doses of placebo at the routine vaccination schedule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete